MARK LESCHLY
CIK 1120545 · last filed 2025-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.06M
Companies
12
Total Filings
38
Lifetime Open-Market Net
$41.67M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CHPT | Director | 848,463 | $7.14 | $6.06M | $0 | 5 | 2025-07-09 |
| ChargePoint Holdings, Inc. (CHPT.WS) Delisted | Director | 439,446 | $20.53 | $9.02M | $0 | 4 | 2021-07-02 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Director | 3,766,667 | $1.54 | $5.80M | $0 | 4 | 2021-06-10 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | 10%+ Owner | 3,568,057 | $15.96 | $56.95M | $81.17M | 3 | 2017-04-03 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 2,787,674 | $10.19 | $28.41M | $11.71M | 8 | 2016-06-24 |
| IntraLinks Holdings, Inc. (IL) Delisted | 10%+ Owner | 3,858,495 | — | — | -$12.50M | 2 | 2015-09-16 |
| NephroGenex, Inc. (NRX) Delisted | 10%+ Owner | 1,073,907 | — | — | -$20.29M | 1 | 2015-01-06 |
| ReachLocal Inc (RLOC) Delisted | 10%+ Owner | 2,756,966 | — | — | -$18.42M | 1 | 2012-11-30 |
| VERENIUM CORP (VRNM) Delisted | Director | 2,595,172 | — | — | $0 | 3 | 2009-02-18 |
| TERCICA INC (TRCA) Delisted | Director | 885,304 | $7.87 | $6.97M | $0 | 2 | 2008-05-22 |
| NITROMED INC (NTMD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-16 |
| SENOMYX INC (SNMX) Delisted | Director | — | — | — | $0 | 1 | 2007-06-04 |
Recent Filings · Page 2 of 4
38 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-22 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-17 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-10 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Conv (C) | +3,766,667 | $0 | EDGAR |
| 2017-04-03 | Tvardi Therapeutics, Inc. (CARA) Delisted | Buy (P) | +3,000,000 | $54.57M | EDGAR |
| 2016-06-24 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Disp (D) | −794 | -$78.8K | EDGAR |
| 2016-03-18 | Tvardi Therapeutics, Inc. (CARA) Delisted | Buy (P) | +2,400,000 | $11.70M | EDGAR |
| 2015-09-16 | IntraLinks Holdings, Inc. (IL) Delisted | Sell (S) | −271,200 | -$2.56M | EDGAR |
| 2015-09-01 | IntraLinks Holdings, Inc. (IL) Delisted | Sell (S) | −970,136 | -$9.94M | EDGAR |
| 2015-06-11 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | +794 | $0 | EDGAR |
| 2015-01-06 | NephroGenex, Inc. (NRX) Delisted | Sell (S) | −1,917,020 | -$20.29M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.